Equities

Astrazeneca Pharma India Ltd

ASTRAZEN:NSI

Astrazeneca Pharma India Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)7,404.55
  • Today's Change149.55 / 2.06%
  • Shares traded129.68k
  • 1 Year change+59.41%
  • Beta0.4598
Data delayed at least 15 minutes, as of Nov 12 2024 10:22 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments5,0565,0034,485
Total Receivables, Net1,8541,3251,050
Total Inventory2,2871,9071,413
Prepaid expenses110118108
Other current assets, total212.000.40
Total current assets9,3278,3557,057
Property, plant & equipment, net648702767
Goodwill, net------
Intangibles, net21----
Long term investments--3129
Note receivable - long term547554550
Other long term assets25----
Total assets10,7809,8498,566
LIABILITIES
Accounts payable1,9652,2791,881
Accrued expenses552520668
Notes payable/short-term debt000
Current portion long-term debt/capital leases183536
Other current liabilities, total1,0361,006742
Total current liabilities3,5713,8393,327
Total long term debt283750
Total debt467286
Deferred income tax------
Minority interest------
Other liabilities, total628675
Total liabilities3,6613,9623,452
SHAREHOLDERS EQUITY
Common stock505050
Additional paid-in capital------
Retained earnings (accumulated deficit)7,0365,8115,044
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity7,1195,8875,114
Total liabilities & shareholders' equity10,7809,8498,566
Total common shares outstanding252525
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.